Northwest Biotherapeutics (NWBO) 6.16 $NWBO
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 4.25 (+0.03), BIIB: 269.16 (-10.72), NWBO: 6.16 (-0.08), CVM: 0.72 (-0.02), CLDX: 12.80 (+1.06), MACK: 9.60 (+0.17), INO: 6.16 (+0.20), NLNK: 34.31 (+1.42), JUNO: 48.64 (+0.84), GALE: 1.74 (+0.01), IMMU: 2.17 (+0.12), ADXS: 11.07 (+0.83), ADRO: 22.06 (+0.32), IMGN: 10.91 (+0.25), AMGN: 149.59 (-0.31), SPPI: 6.20 (+0.07), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), SRNE: 8.61 (+0.05), ONTY: 2.88 (+0.08), IMUC: 0.44 (-0.01), PGNX: 5.77 (+0.26), ARGS: 5.79 (-0.19), GBIM: 2.54 (+0.02), BLCM: 14.65 (+0.39), SGEN: 39.38 (+0.87), KITE: 63.33 (+0.26), MRK: 50.95 (-0.07)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Northwest Biotherapeutics, Inc.
PR Newswire - Wed Sep 23, 5:08PM CDT
Rigrodsky & Long, P.A.:
NWBO: 6.16 (-0.08)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Northwest Biotherapeutics, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit - NWBO
GlobeNewswire - Wed Sep 23, 2:31PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland on behalf of purchasers of Northwest Biotherapeutics, Inc. (Nasdaq:NWBO) ("Northwest Biotherapeutics" or the "Company"
securities during the period between March 8, 2013 and August 20, 2015, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until October 26, 2015 to seek appointment as lead plaintiff.
NWBO: 6.16 (-0.08)
Global Cancer Vaccine Market & Clinical Trial Insight
M2 - Wed Sep 23, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n828vw/global_cancer) has announced the addition of the "Global Cancer Vaccine Market & Clinical Trial Insight" report to their offering. The attractiveness for cancer vaccines has increased in past few years due to their characteristic properties like less side effects, low toxicity and high specificity. Besides, innovations related to novel delivery methods have also made them a lucrative option. Unlike traditional methods, they can be used for targeting the sub-group of cancers without effecting normal cells. Another factor in their favor is their high efficacy levels as compared to the presently available cancer therapeutics. The market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category. The cancer vaccines have to go through a long journey before enjoying the status of blockbuster drug. Presently, they have achieved a lot of success in both therapeutic and preventive field. However, inclination of market and researchers seems to be more towards the preventive category of cancer vaccines. For therapeutic side, it should be noted that novel methods for cancer eradication has been made. The future of cancer vaccines looks optimistic and plenty of cancer vaccines will hit the shelf in coming years. Key Topics Covered - Global Cancer Market Overview - Emergence of Personalized Cancer Vaccines - Platforms for Cancer Vaccines Delivery - Mechanism of Cancer Vaccines - Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country - Global Cancer Vaccine Clinical Pipeline: 298 Vaccines - Marketed Cancer Vaccines: 15 Vaccines - Regulatory Framework for Cancer Vaccines Development & Marketing Companies Mentioned - AVAX Technologies - Advaxis - Celldex Therapeutics - Dendreon Corporation - Galena Biopharma - GlaxoSmithKline - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - KAEL-GemVax - Liponova - MedImmune - Merck - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Recombio - Roche - Sanofi - Seattle Genetics - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/n8...bal_cancer.
INO: 6.16 (+0.20), NWBO: 6.16 (-0.08), MRK: 50.95 (-0.07), CLDX: 12.80 (+1.06), NLNK: 34.31 (+1.42), GALE: 1.74 (+0.01), GSK: 40.22 (+0.06), IMUC: 0.44 (-0.01), NVS: 91.90 (-0.71)
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Northwest Biotherapeutics, Inc.
PR Newswire - Fri Sep 18, 6:45PM CDT
Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Maryland on behalf of persons who purchased or acquired the shares of Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company" (NASDAQ: NWBO) between March 8, 2013 and August 20, 2015, inclusive (the "Class Period" .
NWBO: 6.16 (-0.08)
Northwest Bio CEO: Brain Tumor Vaccine Study Still Suspended
at The Street - Wed Sep 16, 1:24PM CDT
Slightly more than 300 out of a required 348 brain tumor patients are currently enrolled in Northwest Bio's DCVax-L phase III study.
NWBO: 6.16 (-0.08)
NW Bio Presenting New DCVax-Direct Poster At "The Inaugural International Cancer Immunotherapy Conference: Translating Science Into Survival" In New York City On Wednesday, September 16, 2015
PR Newswire - Wed Sep 16, 8:20AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio" , a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that Chief Technical Officer, Dr. Marnix Bosch, will present a new DCVax-Direct poster at the Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival 2015. The Conference is being held at the Sheraton New York Times Square Hotel from September 16th to 19th, 2015.
NWBO: 6.16 (-0.08)
Deadline in Lawsuit for Investors in Northwest Biotherapeutics, Inc (NASDAQ:NWBO) Shares Announced by Shareholders Foundation
GlobeNewswire - Tue Sep 15, 9:40AM CDT
The Shareholders Foundation, Inc. announces that a lawsuit was filed in Maryland on behalf of certain purchasers of shares of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) over alleged Securities Laws Violations by Northwest Biotherapeutics, Inc.
NWBO: 6.16 (-0.08)
NW to Present at 4th Annual SMi Cancer Vaccines Conference in London On Wednesday, September 16, 2015
PR Newswire - Mon Sep 14, 8:51AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio" , a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that CEO Linda Powers will present at the SMi 4th Annual Cancer Vaccines Conference in London on Wednesday, September 16, 2015 at the Marriott Hotel, Regents Park.
NWBO: 6.16 (-0.08)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Northwest Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NWBO
GlobeNewswire - Fri Sep 11, 4:18PM CDT
Pomerantz LLP announces that a class action lawsuit has been filed against Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company" (NASDAQ:NWBO) and certain of its officers. The class action, filed in United States District Court, District of Maryland, Greenbelt Division, and docketed under 8:15-cv-02532, is on behalf of a class consisting of all persons or entities who purchased Northwest Biotherapeutics securities between March 8, 2013 and August 20, 2015 inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
NWBO: 6.16 (-0.08)
ALERT: Rosen Law Firm Reminds Northwest Biotherapeutics, Inc. Investors of Important Class Action Deadline
Business Wire - Thu Sep 10, 12:40PM CDT
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) securities from March 8, 2013 through August 20, 2015, all dates inclusive (the "Class Period" of the important October 26, 2015 lead plaintiff deadline. The lawsuit seeks to recover damages for Northwest Biotherapeutics, Inc. investors under the federal securities laws.
NWBO: 6.16 (-0.08)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Northwest Biotherapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Tue Sep 08, 9:05PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland on behalf of purchasers of Northwest Biotherapeutics, Inc. (NasdaqCM:NWBO) ("Northwest Biotherapeutics" or the "Company" securities during the period between March 8, 2013 and August 20, 2015, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until October 26, 2015 to seek appointment as lead plaintiff.
NWBO: 6.16 (-0.08)
Stull, Stull & Brody Announces Class Action Suit on Behalf of Purchasers of Common Shares of Northwest Biotherapeutics, Inc. -- NWBO
GlobeNewswire - Fri Sep 04, 4:30PM CDT
Stull, Stull & Brody ("SS&B" announces that a class action lawsuit was commenced in the United States District Court for the District of Maryland on behalf of persons who purchased or acquired the shares of Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company" (NASDAQ:NWBO) between March 8, 2013 and August 20, 2015 (the "Class Period" .
NWBO: 6.16 (-0.08)
Law Offices of Marc S. Henzel Announces Securities Class Action Periods
PR Newswire - Thu Sep 03, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com), a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following class periods:
BTH: 5.99 (unch), SPNC: 10.90 (-0.01), NWBO: 6.16 (-0.08), CAM: 66.91 (-0.17), CSTE: 34.68 (-0.20), PIR: 7.53 (+0.13), AAC: 26.22 (-0.54), EBR: 1.48 (+0.04), LOCO: 13.00 (+0.72), MXPT: 4.99 (-0.54)
Northwest Biotherapeutics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors
Business Wire - Tue Sep 01, 12:03PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit has been filed against Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" (NasdaqCM: NWBO) and several officers and directors for acts taken during the period of March 8, 2013 and August 20, 2015 (the "Class Period" .
NWBO: 6.16 (-0.08)
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Northwest Biotherapeutics, Inc. - NWBO
Business Wire - Mon Aug 31, 4:34PM CDT
Rosen Law Firm, a global investor rights law firm, announces that a class action lawsuit has been filed on behalf of purchasers of Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) securities from March 8, 2013 through August 20, 2015, all dates inclusive (the "Class Period" . The lawsuit seeks to recover damages for Northwest Biotherapeutics, Inc. investors under the federal securities laws.
NWBO: 6.16 (-0.08)
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Northwest Biotherapeutics, Inc. to Contact the Firm
Marketwired - Fri Aug 28, 9:10PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company" (NASDAQ: NWBO) of the October 26, 2015 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
NWBO: 6.16 (-0.08)
Northwest Bio Forced to Temporarily Halt Study of Brain Tumor Vaccine
at The Street - Mon Aug 24, 7:53AM CDT
Enrollment of new patients into the DCVax-L study is suspended until the company "submits certain information from the trial for regulatory review," Northwest Bio said.
NWBO: 6.16 (-0.08), MRK: 50.95 (-0.07), CLDX: 12.80 (+1.06), BMY: 61.44 (+0.93)
NW Bio updates current ongoing trial status of DCVax-L for GBM Brain Cancer, with temporary suspension of new screening
M2 - Mon Aug 24, 4:30AM CDT
Biotechnology company Northwest Biotherapeutics (NasdaqCM:NWBO) disclosed on Friday that its Phase III trial of DCVax-L for newly diagnosed glioblastoma multiforme (GBM) is ongoing and the patients enrolled in the trial are continuing to be treated per the protocol including in Germany.
NWBO: 6.16 (-0.08)
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 4.25 (+0.03), BIIB: 269.16 (-10.72), NWBO: 6.16 (-0.08), CVM: 0.72 (-0.02), CLDX: 12.80 (+1.06), MACK: 9.60 (+0.17), INO: 6.16 (+0.20), NLNK: 34.31 (+1.42), JUNO: 48.64 (+0.84), GALE: 1.74 (+0.01), IMMU: 2.17 (+0.12), ADXS: 11.07 (+0.83), ADRO: 22.06 (+0.32), IMGN: 10.91 (+0.25), AMGN: 149.59 (-0.31), SPPI: 6.20 (+0.07), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), SRNE: 8.61 (+0.05), ONTY: 2.88 (+0.08), IMUC: 0.44 (-0.01), PGNX: 5.77 (+0.26), ARGS: 5.79 (-0.19), GBIM: 2.54 (+0.02), BLCM: 14.65 (+0.39), SGEN: 39.38 (+0.87), KITE: 63.33 (+0.26), MRK: 50.95 (-0.07)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Northwest Biotherapeutics, Inc.
PR Newswire - Wed Sep 23, 5:08PM CDT
Rigrodsky & Long, P.A.:
NWBO: 6.16 (-0.08)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Northwest Biotherapeutics, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit - NWBO
GlobeNewswire - Wed Sep 23, 2:31PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland on behalf of purchasers of Northwest Biotherapeutics, Inc. (Nasdaq:NWBO) ("Northwest Biotherapeutics" or the "Company"
securities during the period between March 8, 2013 and August 20, 2015, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until October 26, 2015 to seek appointment as lead plaintiff. NWBO: 6.16 (-0.08)
Global Cancer Vaccine Market & Clinical Trial Insight
M2 - Wed Sep 23, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n828vw/global_cancer) has announced the addition of the "Global Cancer Vaccine Market & Clinical Trial Insight" report to their offering. The attractiveness for cancer vaccines has increased in past few years due to their characteristic properties like less side effects, low toxicity and high specificity. Besides, innovations related to novel delivery methods have also made them a lucrative option. Unlike traditional methods, they can be used for targeting the sub-group of cancers without effecting normal cells. Another factor in their favor is their high efficacy levels as compared to the presently available cancer therapeutics. The market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category. The cancer vaccines have to go through a long journey before enjoying the status of blockbuster drug. Presently, they have achieved a lot of success in both therapeutic and preventive field. However, inclination of market and researchers seems to be more towards the preventive category of cancer vaccines. For therapeutic side, it should be noted that novel methods for cancer eradication has been made. The future of cancer vaccines looks optimistic and plenty of cancer vaccines will hit the shelf in coming years. Key Topics Covered - Global Cancer Market Overview - Emergence of Personalized Cancer Vaccines - Platforms for Cancer Vaccines Delivery - Mechanism of Cancer Vaccines - Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country - Global Cancer Vaccine Clinical Pipeline: 298 Vaccines - Marketed Cancer Vaccines: 15 Vaccines - Regulatory Framework for Cancer Vaccines Development & Marketing Companies Mentioned - AVAX Technologies - Advaxis - Celldex Therapeutics - Dendreon Corporation - Galena Biopharma - GlaxoSmithKline - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - KAEL-GemVax - Liponova - MedImmune - Merck - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Recombio - Roche - Sanofi - Seattle Genetics - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/n8...bal_cancer.
INO: 6.16 (+0.20), NWBO: 6.16 (-0.08), MRK: 50.95 (-0.07), CLDX: 12.80 (+1.06), NLNK: 34.31 (+1.42), GALE: 1.74 (+0.01), GSK: 40.22 (+0.06), IMUC: 0.44 (-0.01), NVS: 91.90 (-0.71)
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Northwest Biotherapeutics, Inc.
PR Newswire - Fri Sep 18, 6:45PM CDT
Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Maryland on behalf of persons who purchased or acquired the shares of Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company"
(NASDAQ: NWBO) between March 8, 2013 and August 20, 2015, inclusive (the "Class Period" . NWBO: 6.16 (-0.08)
Northwest Bio CEO: Brain Tumor Vaccine Study Still Suspended
at The Street - Wed Sep 16, 1:24PM CDT
Slightly more than 300 out of a required 348 brain tumor patients are currently enrolled in Northwest Bio's DCVax-L phase III study.
NWBO: 6.16 (-0.08)
NW Bio Presenting New DCVax-Direct Poster At "The Inaugural International Cancer Immunotherapy Conference: Translating Science Into Survival" In New York City On Wednesday, September 16, 2015
PR Newswire - Wed Sep 16, 8:20AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"
, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that Chief Technical Officer, Dr. Marnix Bosch, will present a new DCVax-Direct poster at the Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival 2015. The Conference is being held at the Sheraton New York Times Square Hotel from September 16th to 19th, 2015. NWBO: 6.16 (-0.08)
Deadline in Lawsuit for Investors in Northwest Biotherapeutics, Inc (NASDAQ:NWBO) Shares Announced by Shareholders Foundation
GlobeNewswire - Tue Sep 15, 9:40AM CDT
The Shareholders Foundation, Inc. announces that a lawsuit was filed in Maryland on behalf of certain purchasers of shares of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) over alleged Securities Laws Violations by Northwest Biotherapeutics, Inc.
NWBO: 6.16 (-0.08)
NW to Present at 4th Annual SMi Cancer Vaccines Conference in London On Wednesday, September 16, 2015
PR Newswire - Mon Sep 14, 8:51AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"
, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that CEO Linda Powers will present at the SMi 4th Annual Cancer Vaccines Conference in London on Wednesday, September 16, 2015 at the Marriott Hotel, Regents Park. NWBO: 6.16 (-0.08)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Northwest Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NWBO
GlobeNewswire - Fri Sep 11, 4:18PM CDT
Pomerantz LLP announces that a class action lawsuit has been filed against Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company"
(NASDAQ:NWBO) and certain of its officers. The class action, filed in United States District Court, District of Maryland, Greenbelt Division, and docketed under 8:15-cv-02532, is on behalf of a class consisting of all persons or entities who purchased Northwest Biotherapeutics securities between March 8, 2013 and August 20, 2015 inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" . NWBO: 6.16 (-0.08)
ALERT: Rosen Law Firm Reminds Northwest Biotherapeutics, Inc. Investors of Important Class Action Deadline
Business Wire - Thu Sep 10, 12:40PM CDT
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) securities from March 8, 2013 through August 20, 2015, all dates inclusive (the "Class Period"
of the important October 26, 2015 lead plaintiff deadline. The lawsuit seeks to recover damages for Northwest Biotherapeutics, Inc. investors under the federal securities laws. NWBO: 6.16 (-0.08)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Northwest Biotherapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Tue Sep 08, 9:05PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland on behalf of purchasers of Northwest Biotherapeutics, Inc. (NasdaqCM:NWBO) ("Northwest Biotherapeutics" or the "Company"
securities during the period between March 8, 2013 and August 20, 2015, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until October 26, 2015 to seek appointment as lead plaintiff. NWBO: 6.16 (-0.08)
Stull, Stull & Brody Announces Class Action Suit on Behalf of Purchasers of Common Shares of Northwest Biotherapeutics, Inc. -- NWBO
GlobeNewswire - Fri Sep 04, 4:30PM CDT
Stull, Stull & Brody ("SS&B"
announces that a class action lawsuit was commenced in the United States District Court for the District of Maryland on behalf of persons who purchased or acquired the shares of Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company" (NASDAQ:NWBO) between March 8, 2013 and August 20, 2015 (the "Class Period" . NWBO: 6.16 (-0.08)
Law Offices of Marc S. Henzel Announces Securities Class Action Periods
PR Newswire - Thu Sep 03, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com), a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following class periods:
BTH: 5.99 (unch), SPNC: 10.90 (-0.01), NWBO: 6.16 (-0.08), CAM: 66.91 (-0.17), CSTE: 34.68 (-0.20), PIR: 7.53 (+0.13), AAC: 26.22 (-0.54), EBR: 1.48 (+0.04), LOCO: 13.00 (+0.72), MXPT: 4.99 (-0.54)
Northwest Biotherapeutics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors
Business Wire - Tue Sep 01, 12:03PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit has been filed against Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics"
(NasdaqCM: NWBO) and several officers and directors for acts taken during the period of March 8, 2013 and August 20, 2015 (the "Class Period" . NWBO: 6.16 (-0.08)
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Northwest Biotherapeutics, Inc. - NWBO
Business Wire - Mon Aug 31, 4:34PM CDT
Rosen Law Firm, a global investor rights law firm, announces that a class action lawsuit has been filed on behalf of purchasers of Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) securities from March 8, 2013 through August 20, 2015, all dates inclusive (the "Class Period"
. The lawsuit seeks to recover damages for Northwest Biotherapeutics, Inc. investors under the federal securities laws. NWBO: 6.16 (-0.08)
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Northwest Biotherapeutics, Inc. to Contact the Firm
Marketwired - Fri Aug 28, 9:10PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company"
(NASDAQ: NWBO) of the October 26, 2015 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers. NWBO: 6.16 (-0.08)
Northwest Bio Forced to Temporarily Halt Study of Brain Tumor Vaccine
at The Street - Mon Aug 24, 7:53AM CDT
Enrollment of new patients into the DCVax-L study is suspended until the company "submits certain information from the trial for regulatory review," Northwest Bio said.
NWBO: 6.16 (-0.08), MRK: 50.95 (-0.07), CLDX: 12.80 (+1.06), BMY: 61.44 (+0.93)
NW Bio updates current ongoing trial status of DCVax-L for GBM Brain Cancer, with temporary suspension of new screening
M2 - Mon Aug 24, 4:30AM CDT
Biotechnology company Northwest Biotherapeutics (NasdaqCM:NWBO) disclosed on Friday that its Phase III trial of DCVax-L for newly diagnosed glioblastoma multiforme (GBM) is ongoing and the patients enrolled in the trial are continuing to be treated per the protocol including in Germany.
NWBO: 6.16 (-0.08)
